In this regard, one of the most widely used assays for PD-L1 IHC evaluation is Ventana SP263, which is currently considered a companion diagnostic by the FDA for atezolizumab as adjuvant treatment in stage II-IIIA non-small cell lung cancer (NSCLC) (11). Here, CD274 is linked to non-small cell lung carcinoma.